2025-03-06
5 分钟The Economist. Hello, this is Alok Jha,
host of Babbage, our weekly podcast on science and technology.
Welcome to Editor's Picks.
We've chosen an unmissable article from the latest edition of The Economist.
Please do have a listen.
Of the many patients who need an organ from a donor, 90% go without.
About 240 million people live with rare genetic diseases, most of which cannot be treated.
Each year, poor diets cause more than 10 million early deaths.
Suffering on such an immense scale can appear hopeless.
However,
a technique called CRISPR gene editing promises to help deal with these issues and many more,
and wise regulation can spur it on.
CRISPR is like an editor that can rewrite DNA letter by letter or gene by gene to remove harmful mutations or add protective ones.
Clinical trials will begin this summer on pig organs edited for transplanting into humans.
Last year the first new therapy went on the market.
It seemingly cures sickle cell disease and beta thalassemia,
two blood disorders that afflict millions.
If ongoing clinical trials succeed,
a one-off therapy could provide lifelong protection against heart attacks.
Farming will benefit too.